<DOC>
	<DOCNO>NCT03033511</DOCNO>
	<brief_summary>This Phase 3 , randomize , double-blind , placebo-controlled , multinational , multicenter study evaluate efficacy rovalpituzumab tesirine maintenance therapy follow first-line platinum-based chemotherapy .</brief_summary>
	<brief_title>A Study Rovalpituzumab Tesirine Maintenance Therapy Following First-Line Platinum-Based Chemotherapy Participants With Extensive Stage Small Cell Lung Cancer ( MERU )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Histologically cytologically confirm extensivestage disease small cell lung cancer ( ED SCLC ) ongoing clinical benefit ( stable disease [ SD ] , partial response [ PR ] , complete response [ CR ] ) follow completion 4 cycle firstline platinumbased therapy At least 3 9 week administration last cycle platinumbased chemotherapy randomization . Participants history central nervous system ( CNS ) metastases prior initiation firstline platinumbased chemotherapy must receive definitive local treatment documentation stable improve CNS disease status Eastern Cooperative Oncology Group ( ECOG ) performance score 0 1 Participants must adequate bone marrow , renal hepatic function Availability archive representative tumor material assessment DLL3 expression Any prior systemic chemotherapy , small molecule inhibitor , immune checkpoint inhibitor , monoclonal antibody , antibodydrug conjugate , radioimmunoconjugates , Tcell cellbased biologic therapy , anticancer therapy describe inclusion criterion Any diseasedirected radiotherapy ( except prophylactic cranial irradiation preplanned radiotherapy CNS metastasis present prior start firstline therapy nonprogressing ) last dose firstline chemotherapy . Prior exposure pyrrolobenzodiazepine ( PBD ) indolinobenzodiazepinebased drug , prior participation rovalpituzumab tesirine clinical trial , know hypersensitivity contraindication rovalpituzumab tesirine excipient contain drug formulation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Extensive-Stage Small Cell Lung Cancer ( ED SCLC )</keyword>
	<keyword>Rovalpituzumab tesirine</keyword>
	<keyword>first-line chemotherapy</keyword>
	<keyword>Cancer</keyword>
	<keyword>Platinum-Based Chemotherapy</keyword>
</DOC>